Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Roche Holding AG

Johnson & Johnson’s oncology drugs portfolio is much smaller than that of Roche. However, J&J's oncology drugs sales growth has been faster in the recent years, and this trend is expected to continue in the coming years, while Roche will likely see slower sales growth, as it faces biosimilar.

Here’s How Johnson & Johnson’s Oncology Drugs Portfolio Compares With That of Roche

A recent Economist article on America's opioid crisis, titled with Johnson & Johnson as lead miscreant, summed up the company's opioid dilemma in a single sentence.

Johnson & Johnson: The Impossible Beckons

The household name has been hit in recent years with product misfires and court judgments challenging public trust and investor faith

Lawsuits, payouts, opioids crisis: what happened to Johnson & Johnson?

Johnson & Johnson has agreed to pay $117 million in a settlement agreement for allegedly hiding the risks of its transvaginal mesh surgical product putting women at risk, officials announced Thursday. New York Attorney General Letitia James and 41 other state AGs resolved the case with J & J and their subsidiary Ethicon, Inc.

Johnson & Johnson settles for $117M in vaginal mesh lawsuit

Coca-Cola

Main Street Capital

Phillips 66

Sherwin-Williams

The Board of Directors of The Coca-Cola Company today announced the election of one new officer, along with declaring the company's regular quarterly dividend.

Daily Dividend Report: Coca Cola, Johnson & Johnson, Main Street Capital, Sherwin-Williams, Phillips 66 Partners

U.S. state attorneys general said on Thursday that Johnson & Johnson and its unit had agreed to pay nearly $117 million to settle litigation over deceptive marketing of the company’s transvaginal surgical mesh devices.

Johnson & Johnson agrees to pay about $117 million to settle vaginal mesh litigation

AmerisourceBergen

Cardinal Health

McKesson

Teva Pharmaceutical

The biggest drug distributors, plus Johnson & Johnson and Teva Pharmaceutical, are reportedly on the brink of a $50 billion deal to settle thousands of cases related to the opioid epidemic.

Drug Suppliers Reportedly Near $50 Billion Deal In Opioid Lawsuits

Jonson & Johnson stock is rebounding, as it appears to be close to agreeing to its role in the opioid crisis.

Johnson & Johnson Stock Rebounds After Earnings

Johnson & Johnson (NYSE: JNJ) shares traded higher by 2% on Wednesday on reports of potential opioid settlement negotiations, but at least a handful of large option traders aren’t optimistic that the J&J rally will last.

Large Option Traders Aren't Buying The Johnson & Johnson Rally

Johnson & Johnson (NYSE: JNJ) stock was on the rise Wednesday following better-than-expected third-quarter earnings and guidance, but analysts are mostly leery of boosting recommendations in light of a string of legal challenges the company faces.

Analysts, Investors Like Johnson & Johnson's Improvement, But Lawsuits Loom

Shares of companies embroiled in the U.S. opioid crisis were trading sharply higher Wednesday following a Tuesday Wall Street Journal report that said three opioid drug distributors are in talks with state and local governments regarding a settlement agreement.

Opioid Drug Companies Rally On Hopes of Broader Settlement

Johnson & Johnson's (JNJ) Management on Q3 2019 Results - Earnings Call Transcript

Johnson & Johnson (JNJ) on Q3 2019 Results - Earnings Call Transcript

UnitedHealth Group

JPMorgan Chase & Co

JNJ, JP Morgan and UnitedHealth all Beat

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 6.00% and 3.22%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Johnson & Johnson (JNJ) Surpasses Q3 Earnings and Revenue Estimates

Bristol-Myers

Caterpillar

CVS Health

Skyworks Solutions

Trade talk optimism sent stocks, especially trade sensitive ones, soaring on Thursday and Friday.

The Best Dividend Stocks To Buy With Trade Uncertainty This High

A shortage of regulatory caution may have caused Johnson & Johnson to push the envelope on making and selling its products.
The post Johnson & Johnson Stock Has Good Numbers, But Bad Verdicts appeared first on InvestorPlace.

Johnson & Johnson Stock Has Good Numbers, But Bad Verdicts

FDA approves Johnson & Johnson's (JNJ) Xarelto to prevent blood clots in hospitalized acutely ill medical patients.

J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion

Johnson & Johnson (NYSE:JNJ) released its third-quarter results on October 15 before market opened.

What Investors Need to Know About Johnson & Johnson’s 3rd-Quarter Results

J&J (JNJ) comes up with encouraging third-quarter 2019 results.

J&J (JNJ) Beats on Q3 Earnings as Sales Rise, Ups 2019 View

Initial Q3 Results Are Better-Than-Expected

When Johnson & Johnson (NYSE: JNJ) reported its most recent quarterly results before the markets opened on Tuesday, the pharmaceutical giant said it had $2.12 in earnings per share (EPS) and $20.73 billion in revenue for its third quarter.

Johnson & Johnson Offers a Strong Start to Earnings Season

The Dow Jones Industrial Average's DJIA, +0.49% biggest gainers were all earnings reporters, while so was the Dow's biggest loser.

UnitedHealth, J.P. Morgan Chase, Johnson & Johnson earnings beats adding combined 119 points to the Dow

J&J (JNJ) beats estimates for earnings and sales in the third quarter of 2019 and raises 2019 guidance.

J&J (JNJ) Beats Q3 Earnings & Sales, Shares Rise

Johnson & Johnson (NYSE: JNJ) reported third-quarter earnings of $2.12 per share on Tuesday, beating the $2 Street estimate.

News for Johnson & Johnson Stock (JNJ)